Therapy for progressive supranuclear palsy: past and future
Dysfunction of multiple brain systems in progressive supranuclear palsy (PSP) has complicated attempts to treat the disease. Neuro-transmitter replacement strategies targeting the dopaminergic, cholinergic, and serotonergic systems have been unsuccessful. In order to bypass the degenerated corticostriato-pallidal loop, we adminstered the adrenergic agonist idazoxan (IDA) to treat PSP in two randomized double-blind, placebo controlled, crossover studies. Approximately one half of patients enrolled in these studies showed statistically significant improvement in balance and manual dexterity while taking IDA compared to placebo. These results suggest that new therapies that target structures outside of the basal ganglia may be useful for symptomatic treatment of PSP. Applying this strategy and developing treatments that arrest or reverse clinical deterioration in PSP will require improved understanding of the process underlying the illness.
KeywordsProgressive Supranuclear Palsy Globus Pallidus Progressive Supranuclear Palsy Locus Ceruleus Progressive Supranuclear Palsy Patient
Unable to display preview. Download preview PDF.
- Agid Y, Javoy-Agid F, Ruberg M, Pillon B, Dubois B, Duyckaerts C, Hauw JJ, Baron JC, Scatton B (1986) Progressive supranuclear palsy: anatomoclinical and biochemical considerations. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 191–206.Google Scholar
- Diagnostic and statistical manual of mental disorders, 3rd edn (1987) American Psychiatric Association, Washington DC.Google Scholar
- Flowers KA, Robertson C (1985) The effect of Parkinson’s disease on the ability to maintain a mental set. JNNP 48: 517–529.Google Scholar
- Golden CJ, Hammeke TA, Purisch AD (1980) Manual for the Luria-Nebraska neuro-psychological battery. Western Psychological Services, Los Angeles.Google Scholar
- Hamilton M (1967) A rating scale for depression. JNNP 5: 135–140.Google Scholar
- Jellinger K, Riederer P, Tomonoga M (1980) Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm [Suppl] 16: 111–128.Google Scholar
- Lang AE, Fahn S (1989) Assessment of Parkinson’s disease. In: Munsat TL (ed) Quantification of neurological deficit. Butterworths, London, pp 271–284.Google Scholar
- Narabayashi H, Timohoshi K, Yokochi F, Nagatsu T (1986) Clinical effects of L-threo-3,4-dyhydroxyphenylserine in cases of parkinsonism and pure akinesia. In: Yahr MD, Bergmann KJ (eds) Advances in neurology, vol 45. Raven Press, New York, pp 550–559.Google Scholar
- Neophytides A, Lieberman AN, Goldstein M, Gopinathan G, Leibowitz M, Bock J, Walker R (1982) The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. JNNP 45: 261–263.Google Scholar
- Randt CT, Brown ER, Osborne DP (1980) A memory test for longitudinal measurement of mild to moderate deficits. Clin Neuropsychol 2: 184–194.Google Scholar
- Weschler D (1981) Weschler adult intelligence scale, revised. Psychological Corporation, New York.Google Scholar